RxDoctor Payments Data

Joseph Turner, MD

Urology · Anchorage, AKNPI 1134150410

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $201 and has fallen 58.6% since, to $83 in 2025. That places this record below the midpoint for urology clinicians in AK, where the typical reported total is $2,491.

$777in general payments, 2019–2025

Across 34 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • C. R. Bard, Inc. & Subsidiaries$173
  • Rochester Medical Corporation$146
  • Astellas Pharma US Inc$105
  • AbbVie$67
  • Myriad Genetic Laboratories, Inc.$59
  • Pfizer$51
  • plus $177 from 7 others

What the payments were for

  • Food & beverage$77099%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$777 in reported general payments places this provider in the 30th percentile of 28 urology providers in Alaska.

See all urology providers in Alaska

Medicare billing

Part B allowed, 2024
$204,439
Medicare patients
527
Services billed
2,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron41$51,118
GemtesaVibegron16$18,742
Tamsulosin Hcl250$5,382
Dutasteride59$3,733
Alfuzosin Hcl ErAlfuzosin Hcl72$3,067
Potassium Citrate ErPotassium Citrate20$2,760
Tadalafil41$1,929
Finasteride100$1,876
Silodosin20$1,716
Methenamine Hippurate39$1,606
Testosterone11$860
Testosterone Cypionate21$654
Oxybutynin Chloride ErOxybutynin Chloride23$563
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$321
Allopurinol15$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$105$51,11841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 28 urology providers in Alaska.

Other urology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →